GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of GPED (gemcitabine, pegaspargase, etoposide, and dexamethasone) regimen in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients
Extranodal NK/T-cell Lymphoma
DRUG: Gemcitabine|DRUG: Pegaspargase|DRUG: Etoposide|DRUG: Dexamethasone
overall response rate, evaluated by PET-CT and MRI, according to Lugano 2014 criteria, 24 weeks ±7 days
complete response rate, evaluated by PET-CT and MRI, according to Lugano 2014 criteria, 24 weeks ±7 days|1-year progression free survival rate, time from date of enrollment to date of disease progression, death of any reason, whichever comes first, up to 1year after enrollment|1-year overall survival rate, time from date of enrollment to date death of any reason, up to 1year after enrollment
The purpose of this study is to evaluate the efficacy and safety of GPED (gemcitabine, pegaspargase, etoposide, and dexamethasone) regimen in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients